Organon & Co. (NYSE:OGN) Shares Sold by Fayez Sarofim & Co

Fayez Sarofim & Co reduced its stake in shares of Organon & Co. (NYSE:OGN) by 27.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,595 shares of the company’s stock after selling 8,204 shares during the quarter. Fayez Sarofim & Co’s holdings in Organon & Co. were worth $322,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of OGN. Horizon Bancorp Inc. IN increased its position in shares of Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after purchasing an additional 1,585 shares in the last quarter. Millstone Evans Group LLC purchased a new stake in Organon & Co. in the fourth quarter valued at approximately $29,000. Larson Financial Group LLC grew its position in shares of Organon & Co. by 345.4% during the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after acquiring an additional 1,734 shares during the last quarter. Riverview Trust Co raised its position in Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after purchasing an additional 1,292 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in Organon & Co. by 92.2% during the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on OGN shares. Morgan Stanley lowered their price target on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays lowered their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.60.

Organon & Co. Trading Down 4.0 %

NYSE:OGN opened at $10.67 on Tuesday. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of 3.20, a PEG ratio of 0.90 and a beta of 0.73. Organon & Co. has a 1 year low of $10.45 and a 1 year high of $23.10. The stock has a fifty day moving average price of $14.17 and a two-hundred day moving average price of $15.32. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. As a group, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a dividend of $0.28 per share. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 10.50%. Organon & Co.’s payout ratio is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.